Not yet recruiting
Aspirin in Acute Pneumonia in the Elderly: a Multicenter, Double-blind, Randomized, Placebo-controlled Trial.
NCT06774846· Phase 3· Centre Hospitalier Universitaire Dijon· Source
Not yet recruiting
A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma
NCT07612787· Phase 1/2· Centre Hospitalier Universitaire de Saint Etienne· Source
Not yet recruiting
Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
NCT07739459· Phase 2· The Lymphoma Academic Research Organisation· Source
Not yet recruiting
Evaluation of the Efficacy and Safety of Bimekizumab (BZK) or Adalimumab (ADA) in the Treatment of Anterior Chest Wall Pain Associated With Active Axial Spondyloarthritis Refractory to NSAIDs With Hypothesis of Superiority of Bimekizumab
NCT07836283· Phase 3· University Hospital, Rouen· Source
Not yet recruiting
Early Corticosteroids in Severe Influenza Pneumonia, a phase III randomized controlled trial
2025-524976-40-00· Phase 3· Centre Hospital Region Metz Thionville· Source
Not yet recruiting
Prospective evaluation of response to treatment by analysis of measurable residual disease in younger adult patients (18-60 years) with acute myeloid leukemia (AML). The Backbone InterGroup (BIG)-2 umbrella trial from the Acute Leukemia French Intergroup (ALFA, FILO) - BIG2
2026-525759-96-00· Phase 4· Centre Hospitalier Universitaire De Toulouse· Source
Not yet recruiting
Multicenter phase III non-Inferiority trial of treatment reduction in patients with advanced hormonesensitive breast cancer in complete response
2026-526319-12-00· Phase 3· Unicancer· Source
Not yet recruiting
Topical Clobetasol Propionate for Inflammatory Hand Osteoarthritis
NCT07812701· Phase 2· Assistance Publique - Hôpitaux de Paris· Source
Not yet recruiting
Immunotherapy with a JAK1/JAK2 inhibitor (baricitinib) and an mTORC1 inhibitor (sirolimus), alone and in combination, for the control of HIV-1 replication after antiretroviral treatment interruption: a phase II multicenter, multi-arm, multi-stage, randomized, double-blind, placebo-controlled, adaptative trial
NCT07081763· Phase 2· ANRS Maladies Infectieuses Emergentes· Source
Not yet recruiting
OBINUSS - A trial to evaluate a new drug in systemic sclerosis: obinutuzumab.
2025-524003-68-00· Phase 2· Assistance Publique Hopitaux De Paris· Source
Recruiting
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993· Phase 3· AstraZeneca· Source
Recruiting
PALETTE - Trial for personalisation of sepsis treatment in children and adults
2025-521371-31-00· Phase 2· Assistance Publique Hopitaux De Paris· Source
Not yet recruiting
A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL
2024-516570-30-00· Phase 2· Centre Hospitalier De Versailles· Source
Recruiting
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer ( RAINFOL-03 )
2024-519818-31-01· Phase 3· Genmab A/S· Source
Not yet recruiting
Comparison of Two Etoposide Initiation Strategies for Severe Hemophagocytic Lymphohistiocytosis
NCT07497438· Phase 3· Assistance Publique - Hôpitaux de Paris· Source
Recruiting
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
NCT07431827· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
FILOWM4-WaZaBi: "Open label phase 2 study evaluating the efficacy and tolerance of a zanubrutinib and BGB-11417 combination in patients previously treated for Waldenström macroglobulinemia"
2023-505781-28-00· Phase 2· French Innovative Leukemia Organization· Source
Recruiting
Strategies for zoledronic acid post-denosumab discontinuation in postmenopausal osteoporosis
2024-511871-13-00· Phase 4· Centre Hospitalier Universitaire De Toulouse· Source
Recruiting
Prophylactic Anti-aRrhythmic therapy with Amiodarone in critically ill patients admitted for an out-of-hospital Cardiac Arrest with initial shockable rhythm._PARACA
2023-510099-30-00· Phase 3· Centre Hospitalier De Versailles· Source
Active, not recruiting
A Phase 2 Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis
2024-519291-11-00· Phase 2· AbbVie Deutschland GmbH & Co. KG· Source
Recruiting
Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer
NCT06606730· Phase 3· UNICANCER· Source
Recruiting
Evaluation of 200 mg of Rituximab Every 6 Months as Maintenance Treatment of Rituximab-treated Patients With Rheumatoid Arthritis
NCT06906549· Phase 4· University Hospital, Strasbourg, France· Source
Recruiting
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
NCT06918002· Phase 3· Intergroupe Francophone du Myelome· Source
Recruiting
Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors
NCT05974774· Phase 3· European Organisation for Research and Treatment of Cancer - EORTC· Source
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06935357· Phase 3· Biogen· Source
Recruiting
MODULO
NCT06774872· Phase 3· Centre De Recherches Et D'Etudes Sur La Pathologie Tropicale Et Le Sida· Source
Recruiting
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
NCT06641414· Phase 3· Ascentage Pharma Group Inc.· Source
Recruiting
Lessening Organ Dysfunction with VITamin C in septic ARDS
NCT04404387· Phase 3· Assistance Publique Hopitaux De Paris· Source
Recruiting
Comparison of Landiolol versus standard of care for prevention of mortality in patients hospitalized for a septic shock with hypercontractlity: an open label prospective randomized study
2024-518251-31-00· Phase 3· Centre Hospitalier Universitaire Amiens Picardie· Source
Recruiting
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
NCT06428019· Phase 3· AbbVie· Source
Recruiting
FILOCLL015 - GLORIFY - A phase 2 study evaluating the bispecific CD3xCD20 antibody GLOfitamab in combination with rituximab or obinutuzumab plus cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) in patients with RIchter syndrome as Frontline therapY
2022-501554-11-00· Phase 2· French Innovative Leukemia Organization· Source
Recruiting
Global Trial in APG2575 for Patients With CLL/SLL
NCT06104566· Phase 3· Ascentage Pharma Group Inc.· Source
Recruiting
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356· Phase 3· Amgen· Source
Active, not recruiting
Beta-lactam Intermittent Versus Continuous Infusion and Combination Antibiotic Therapy in Sepsis
NCT05681442· Phase 4· Assistance Publique - Hôpitaux de Paris· Source
Active, not recruiting
Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma
NCT05889221· Phase 2· Poitiers University Hospital· Source
Active, not recruiting
A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML
NCT05199051· Phase 2· Centre Antoine Lacassagne· Source
Recruiting
Intensification of Blood Pressure Lowering Therapeutics Based on Diuretics Versus Usual Management for Uncontrolled Hypertension IN Patients With Moderate to Severe Chronic Kidney Disease
NCT05732727· Phase 3· University Hospital, Tours· Source
Active, not recruiting
A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission
NCT05622708· Phase 4· Novartis Pharmaceuticals· Source
Active, not recruiting
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT05714202· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
ASPIC - Antimicrobial Stewardship for Ventilator Associated Pneumonia in Intensive Care
2024-513327-16-00· Phase 3· Assistance Publique Hopitaux De Paris· Source
Recruiting
Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
NCT05181735· Phase 1/2· Groupe Francophone des Myelodysplasies· Source
Recruiting
De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction
NCT05255302· Phase 2/3· Intergroupe Francophone de Cancerologie Thoracique· Source
Active, not recruiting
Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line
NCT05201547· Phase 3· ARCAGY/ GINECO GROUP· Source
Active, not recruiting
MInimal Residual Disease Adapted Strategy
NCT04934475· Phase 3· Intergroupe Francophone du Myelome· Source
Recruiting
Extending the Time Window for Tenecteplase by Recanalization of Basilar Artery Occlusion in Posterior Circulation Stroke
NCT05105633· Phase 2/3· University of Melbourne· Source
Active, not recruiting
Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).
NCT04751877· Phase 3· Poitiers University Hospital· Source
Active, not recruiting
Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis
NCT04870203· Phase 3· University Hospital, Bordeaux· Source
Active, not recruiting
Double blind, multicentric, randomized, placebo-controlled trial, evaluating the efficacy of 24-month of bezafibrate in primary sclerosing cholangitis with persistent cholestasis despite ursodeoxycholic acid therapy (BEZASCLER
NCT04309773· Phase 3· Assistance Publique Hopitaux De Paris· Source
Recruiting
Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary
NCT04325425· Phase 2· Centre Hospitalier Universitaire Dijon· Source
Recruiting
Randomized phase 3 trial comparing FOLFOX to gemcitabine in metastatic first-line in patients with pancreatic adenocarcinoma and non-fit for FOLFIRINOX (GEMFOX)
NCT04167007· Phase 2/3· Assistance Publique Hopitaux De Paris· Source
Showing 50 of 57.